...
首页> 外文期刊>Drug discovery today >The positive impacts of Real-World Data on the challenges facing the evolution of biopharma
【24h】

The positive impacts of Real-World Data on the challenges facing the evolution of biopharma

机译:现实世界数据对生物食收演变面临挑战的积极影响

获取原文
获取原文并翻译 | 示例
           

摘要

Demand for healthcare services is unprecedented. Society is struggling to afford the cost. Pricing of biopharmaceutical products is under scrutiny, especially by payers and Health Technology Assessment agencies. As we discuss here, rapidly advancing technologies, such as Real-World Data (RWD), are being utilized to increase understanding of disease. RWD, when captured and analyzed, produces the Real-World Evidence (RWE) that underpins the economic case for innovative medicines. Furthermore, RWD can inform the understanding of disease, help identify new therapeutic intervention points, and improve the efficiency of research and development (R&D), especially clinical trials. Pursuing precompetitive collaborations to define shared requirements for the use of RWD would equip service-providers with the specifications needed to implement cloud-based solutions for RWD acquisition, management and analysis. Only this approach would deliver cost-effective solutions to an industry-wide problem.
机译:医疗保健服务的需求是前所未有的。 社会正在努力负担得起成本。 生物制药产品的定价遭到审查,特别是通过付款人和健康技术评估机构。 正如我们在此讨论的那样,正在利用迅速推进技术,例如现实世界数据(RWD)来增加对疾病的理解。 当捕获和分析时,RWD产生了基于创新药物的经济案例的真实证据(RWE)。 此外,RWD可以告知对疾病的理解,有助于确定新的治疗介入点,提高研究和开发效率(研发),特别是临床试验。 追求预先竞争的合作来定义使用RWD的共享要求将装备服务提供商,其中规范实现基于云的解决方案的RWD采集,管理和分析。 只有这种方法将为行业范围的问题提供成本效益的解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号